Articles from Veranex

Veranex, the industry’s first Innovation CRO (iCRO) redefining end-to-end MedTech development, today announced the appointment of Jose Pablo Morales, MD as Chief Medical Officer (CMO). Dr. Morales’s addition to the executive leadership team reinforces Veranex’s commitment to accelerating innovation responsibly, helping clients navigate a rapidly evolving regulatory landscape while driving clinical and commercial success.

Veranex, a global provider of product development and contract research services, today introduced the industry’s first Innovation CRO (iCRO)—an integrated development and research platform engineered to move medical devices and in-vitro diagnostics (IVDs) from concept to commercial success faster, with tighter budget control and a built-in path to payer adoption.

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today that it has acquired Fusion Biotec (Fusion), a design and engineering leader for complex electro-mechanical diagnostic instrumentation and medical devices located in Orange, California. Veranex and Fusion’s combined expertise and specialization in design and engineering, with Veranex’s established infrastructure and expertise for full-scale, rapid development of diagnostic and IVD solutions and Fusion’s ultra-quick concept-to-production model, ensures a continued focus on accelerating the development of diagnostic and medical technology solutions for regulatory and commercial success.

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today the appointment of industry veteran Tom Daulton as chief executive officer (CEO). David Dockhorn, who previously served in this role, is assuming the newly created role of chief operating officer (COO).

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced today that it has acquired an ecosystem of full-service medical device consultancy companies, providing regulatory and clinical affairs, quality assurance, and biocompatibility services for medical devices and in vitro diagnostic (IVD) devices. Based in Sweden, this ecosystem includes Devicia, a full-service partner offering clinical expertise; Clarvin, a provider of strategic guidance in regulatory affairs and quality assurance; and affiliate companies Kickfile, Lea Reg, and Limulus Bio. Together with the recent acquisition of Swiss-based Medidee, these companies further expand Veranex’s European reach and build regulatory, clinical, and quality service segments. This specifically strengthens Veranex’s medical device regulation (MDR) and in vitro diagnostic regulation (IVDR) strategy, adding expertise in biological evaluations and medical device software and expanding infrastructure and designating local representation in the European Union and United Kingdom.

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced today that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations (EU-MDR/IVDR) challenges supports truly full-service MedTech product development and commercialization.

Veranex — the only global, tech-enabled product development services provider focused on the medical technology industry — today announced strategic partnerships with Accelmed Partners II and Lauxera Capital Partners. Accelmed and Lauxera join existing investor Summit Partners to help further accelerate Veranex’s strategic development as the company continues to expand its global operations. Uri Geiger, managing partner with Accelmed, and Samuel Levy, co-founder of Lauxera, have joined the Veranex board of directors.

Veranex, the only global, tech-enabled product development services provider focused on the medical technology industry, today announced its latest acquisition, Worrell, further expanding its offerings and geographic reach. As one integrated company, Veranex delivers compelling strategic, operational, and financial benefits by combining the skills and expertise needed for developing breakthrough medical technologies from concept to commercialization. Veranex is the product of six complementary acquisitions backed by growth investor Summit Partners: Ximedica, Quartesian, Boston Healthcare Associates, Experien Group, IMM Recherche, and now Worrell.

Veranex, the first concept-to-commercialization global service provider dedicated to the MedTech industry, today announced the acquisition of IMMR, a leading preclinical science organization that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators. IMMR is located in Paris, France.

Veranex, the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies. Formed in partnership with global growth investor Summit Partners, Veranex provides the global medical technology industry integrated product development strategies and services across the product life cycle. As a result of this transaction, Veranex’s West Coast operations offer a unique, client-responsive consulting model that adjusts to meet client program requirements.

Veranex today announced the formation of the first concept-to-commercialization global service provider dedicated to the medtech industry. Formed in partnership with global growth investor Summit Partners, the Veranex platform is designed to provide the global medical technology industry with access to real-time integrated strategy across the product life cycle. As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.